Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Syndax Pharmaceuticals Inc

Healthcare US SNDX

18.34USD
-0.05(0.27%)

Last update at 2026-06-03T20:04:00Z

Day Range

18.1018.58
LowHigh

52 Week Range

11.2125.34
LowHigh

Fundamentals

  • Previous Close 18.39
  • Market Cap1713.34M
  • Volume1245511
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-263.44099M
  • Revenue TTM126.58M
  • Revenue Per Share TTM2.17
  • Gross Profit TTM 139.71M
  • Diluted EPS TTM-3.24

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -149.33800M 24.93M -73.15800M -56.04700M -73.96100M
Minority interest - - - - -
Net income -143.74900M 24.93M -73.06900M -55.95500M -73.96100M
Selling general administrative 33.26M 25.24M 22.50M 16.06M 17.29M
Selling and marketing expenses - - - - -
Gross profit - 139.71M 1.52M 1.52M 1.52M
Reconciled depreciation 0.03M 0.04M 0.09M 0.09M 0.08M
Ebit -151.79000M 26.18M -71.51200M -57.63100M -75.95400M
Ebitda -151.75700M 26.22M -71.42300M -57.53900M -75.87600M
Depreciation and amortization 0.03M 0.04M 0.09M 0.09M 0.08M
Non operating income net other - 0.60M 0.62M -0.07900M -0.02700M
Operating income -151.75700M 26.22M -71.42300M -57.53900M -75.87600M
Other operating expenses 151.76M 113.49M 72.94M 59.06M 77.39M
Interest expense 3.14M 1.90M 2.36M 1.57M 1.94M
Tax provision - - - - -
Interest income 5.87M 0.40M 0.84M 1.57M 1.94M
Net interest income 2.73M -1.49600M -1.51600M 1.57M 1.94M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.58900M -0.04300M -0.08900M -0.09200M 1.92M
Total revenue 0.00000M 139.71M 1.52M 1.52M 1.52M
Total operating expenses 151.76M 113.49M 72.94M 59.06M 77.39M
Cost of revenue - - - - 0.00000M
Total other income expense net 2.42M -1.29400M -1.73500M 1.49M 1.92M
Discontinued operations - - - - -
Net income from continuing ops -149.33800M 24.93M -73.15800M -56.04700M -73.96100M
Net income applicable to common shares -149.33800M 24.93M -77.06400M -56.04700M -73.96100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 612.88M 497.24M 449.66M 300.61M 63.52M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.06M 0.19M 0.38M 0.34M 0.76M
Total liab 58.68M 29.79M 41.29M 48.42M 31.93M
Total stockholder equity 554.20M 467.45M 408.37M 252.19M 31.60M
Deferred long term liab - - - - -
Other current liab 0.89M 24.28M 1.89M 11.25M 10.20M
Common stock 0.00800M 0.00700M 0.00600M 0.00500M 0.00300M
Capital stock 0.00800M 0.00700M 0.00600M 0.00500M 0.00300M
Retained earnings -902.40000M -693.04000M -543.70200M -568.62800M -495.47000M
Other liab - - - 11.62M 13.14M
Good will - - - - -
Other assets - 0.92M 449.66M 1.56M 0.20M
Cash 295.39M 74.36M 221.97M 115.24M 24.61M
Cash and equivalents - - - - -
Total current liabilities 58.10M 29.07M 20.68M 18.87M 18.37M
Current deferred revenue 38.97M - 12.76M 1.52M 1.52M
Net debt -293.75900M -73.19500M -200.99800M -94.70700M -23.71200M
Short term debt 1.05M 0.44M 0.36M 2.60M 0.48M
Short long term debt - - - 2.29M -
Short long term debt total 1.64M 1.16M 20.97M 20.54M 0.90M
Other stockholder equity 1456.37M 1161.29M 952.02M 820.82M 527.07M
Property plant equipment - 1.06M 0.28M 0.19M 1.00M
Total current assets 580.88M 481.27M 448.40M 298.86M 62.33M
Long term investments 29.83M 5.47M - - -
Net tangible assets - 467.45M 408.37M 252.19M 31.60M
Short term investments 282.19M 410.04M 217.97M 177.82M 35.17M
Net receivables 1.23M 4.06M 0.43M 0.17M 0.12M
Long term debt - - 19.89M 17.83M -
Inventory 2.00M -4.25100M 7.65M 5.28M 1.68M
Accounts payable 17.19M 4.35M 5.67M 3.51M 6.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.22M -0.80600M 0.04M -0.00400M -0.31000M
Additional paid in capital - - - - -
Common stock total equity - - 0.00600M 0.00500M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - -543.70200M -568.62800M -495.47000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.68M 9.44M 0.98M 1.27M 0.20M
Deferred long term asset charges - - - - -
Non current assets total 32.00M 15.96M 1.26M 1.75M 1.19M
Capital lease obligations 1.64M 1.16M 1.07M 0.42M 0.90M
Long term debt total - - 19.89M 17.83M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -186.18800M -40.74400M -142.53000M 12.78M 51.59M
Change to liabilities -1.31900M 4.93M -2.10300M 1.33M 0.18M
Total cashflows from investing activities -186.18800M -40.87300M -142.53000M 12.78M 51.40M
Net borrowings -20.99600M -20.99600M 19.73M 19.73M 19.73M
Total cash from financing activities 172.25M 118.46M 304.42M 28.57M 15.73M
Change to operating activities 2.98M 1.38M -3.74700M -3.46300M 2.01M
Net income -149.33800M 24.93M -73.15800M -56.04700M -73.96100M
Change in cash -147.60900M 106.72M 90.63M -9.26100M -1.40400M
Begin period cash flow 222.08M 115.36M 24.72M 33.98M 35.39M
End period cash flow 74.47M 222.08M 115.36M 24.72M 33.98M
Total cash from operating activities -133.67500M 29.13M -71.26000M -50.61200M -68.53100M
Issuance of capital stock 181.79M 86.34M 277.71M 28.21M 15.50M
Depreciation 0.03M 0.04M 0.09M 0.09M 0.08M
Other cashflows from investing activities - - - 12.78M 51.59M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 24.85M 284.69M 28.57M 15.72M
Other cashflows from financing activities 11.46M 7.28M 26.71M 0.36M 0.23M
Change to netincome 13.97M 12.93M 9.45M 6.00M 6.21M
Capital expenditures 0.00000M 0.13M 0.13M 0.13M 0.19M
Change receivables - - - - -
Cash flows other operating - -14.29600M -5.31600M -1.21000M -0.48400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 106.72M 90.63M -9.26100M -1.40400M
Change in working capital 1.66M -9.59700M -7.93400M -0.24100M -0.30200M
Stock based compensation 16.02M 13.32M 9.06M 6.00M 6.20M
Other non cash items -2.04500M 0.19M 0.82M 0.36M 0.01M
Free cash flow -133.67500M 29.00M -71.26000M -50.61200M -68.71800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SNDX
Syndax Pharmaceuticals Inc		 -0.05 0.27% 18.34 - - 12.67 3.33 9.00 -6.0797
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals Inc

35 Gatehouse Drive, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Michael A. Metzger M.B.A. CEO & Director 1971
Dr. Briggs W. Morrison M.D. Pres, Head of R&D and Director 1960
Dr. Anjali Ganguli Ph.D. Chief Bus. Officer 1976
Dr. Peter Ordentlich B.Sc., Ph.D. Co-Founder & Chief Scientific Officer 1969
Dr. Richard A. Heyman Ph.D. Co-Founder 1957
Dr. Ronald M. Evans Ph.D. Co-Founder, Advisor and Chair of Scientific Advisory Board NA
Dr. Michael Downes Ph.D. Co-Founder NA
Mr. Keith Alan Goldan CPA Chief Financial Officer 1971
Mr. Alexander Nolte VP & Chief Accounting Officer 1973
Sharon Klahre VP of Investor Relations & Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions